Workskop on Cellular and Oligonucleotide therapies -

17th October 2020

Germany, Berlin

On October 17th, RGCC founder and genetics pioneer Dr Ioannis Papasotiriou and members of RGCC’s scientific team hosted a workshop regarding Cellular and Oligonucleotide therapies.

Need help?

Can brain tumours also be tested with a blood sample?

No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.

Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?

Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.

Which test is the most comprehensive test?

The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.

How do online consultations work?

Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs. The online consultation will be available via the Cancer A-Z app soon… please keep checking the app for updates.

Will online consultations take place via Zoom, Skype or another method?

Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.

Didn't find an answer to your question? Contact us directly.

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more

Cookies